{"nctId":"NCT01453855","briefTitle":"Travoprost 3-Month Safety and Efficacy Study","startDateStruct":{"date":"2011-11"},"conditions":["Open-Angle Glaucoma","Ocular Hypertension"],"count":1099,"armGroups":[{"label":"Travoprost 0.003%","type":"EXPERIMENTAL","interventionNames":["Drug: Travoprost ophthalmic solution, 0.003%"]},{"label":"TRAVATAN","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Travoprost ophthalmic solution, 0.004%"]}],"interventions":[{"name":"Travoprost ophthalmic solution, 0.003%","otherNames":[]},{"name":"Travoprost ophthalmic solution, 0.004%","otherNames":["TRAVATANÂ®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of open-angle glaucoma (including open-angle glaucoma with pseudoexfoliation or pigment dispersion) or ocular hypertension.\n* Qualifying intraocular pressure at both eligibility visits.\n* Understand and sign an informed consent form.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Women of childbearing potential if pregnant, breast-feeding, or not on adequate birth control.\n* Severe central visual field loss in either eye.\n* Chronic, recurrent or severe inflammatory eye disease.\n* Best corrected visual acuity (BCVA) score worse than 55 ETDRS letters (equivalent to 20/80 Snellen).\n* Any abnormality preventing reliable applanation tonometry.\n* Hypersensitivity to prostaglandin analogs or to any component of the study medications.\n* Therapy with another investigational agent within 30 days prior to the Screening Visit.\n* Other protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Intraocular Pressure (IOP) at Week 2, Week 6, and Month 3 for Each Assessment Time Point (8 AM, 10 AM, and 4 PM)","description":"As measured by Goldmann applanation tonometry. One eye from each subject was chosen as the study eye and only the study eye was used in the efficacy analysis. A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.4","spread":"0.16"},{"groupId":"OG001","value":"19.5","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":"0.16"},{"groupId":"OG001","value":"18.6","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":"0.16"},{"groupId":"OG001","value":"18.3","spread":"0.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":"0.16"},{"groupId":"OG001","value":"19.3","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.5","spread":"0.16"},{"groupId":"OG001","value":"18.6","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":"0.16"},{"groupId":"OG001","value":"18.1","spread":"0.17"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":"0.17"},{"groupId":"OG001","value":"19.3","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":"0.17"},{"groupId":"OG001","value":"18.6","spread":"0.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.0","spread":"0.16"},{"groupId":"OG001","value":"18.0","spread":"0.17"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":442},"commonTop":["Ocular hyperaemia","Conjunctival hyperaemia"]}}}